Fulcrum Therapeutics (FULC) Short Interest Ratio & Short Volume $8.50 +0.25 (+3.03%) Closing price 09/25/2025 04:00 PM EasternExtended Trading$8.72 +0.22 (+2.59%) As of 09/25/2025 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Fulcrum Therapeutics Short Interest DataFulcrum Therapeutics (FULC) has a short interest of 3.72 million shares, representing 7.39% of the float (the number of shares available for trading by the public). This marks a -36.08% decrease in short interest from the previous month. The short interest ratio (days to cover) is 5.7, indicating that it would take 5.7 days of the average trading volume of 428,910 shares to cover all short positions.Current Short Interest3,720,000 sharesPrevious Short Interest5,820,000 sharesChange Vs. Previous Month-36.08%Dollar Volume Sold Short$24.11 millionShort Interest Ratio5.7 Days to CoverLast Record DateAugust 31, 2025Outstanding Shares54,090,000 sharesShort Percent of Float7.39%Today's Trading Volume868,095 sharesAverage Trading Volume428,910 sharesToday's Volume Vs. Average202% Short Selling Fulcrum Therapeutics? Sign up to receive the latest short interest report for Fulcrum Therapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Get Report View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartFULC Short Interest Over TimeFULC Days to Cover Over TimeFULC Percentage of Float Shorted Over Time Fulcrum Therapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 8/31/20253,720,000 shares $24.11 million -36.1%7.4%5.7 $6.48 8/15/20255,820,000 shares $39.69 million +15.9%N/A8.7 $6.82 7/31/20255,020,000 shares $33.78 million +2.0%10.0%7.1 $6.73 7/15/20254,920,000 shares $38.57 million -12.8%N/A7.8 $7.84 6/30/20255,640,000 shares $38.80 million -3.1%11.2%9.2 $6.88 6/15/20255,820,000 shares $39.87 million +2.5%11.6%10.8 $6.85 5/31/20255,680,000 shares $38.96 million +15.2%11.0%10.2 $6.86 5/15/20254,930,000 shares $32.54 million +45.0%9.5%8.9 $6.60 4/30/20253,400,000 shares $13.09 million -4.5%N/A6.8 $3.85 4/15/20253,560,000 shares $10.82 million -4.6%6.9%8.9 $3.04 Get the Latest News and Ratings for FULC and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Fulcrum Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 3/31/20253,730,000 shares $10.74 million -28.5%7.2%8.3 $2.88 3/15/20255,220,000 shares $16.29 million +6.1%10.1%8.3 $3.12 2/28/20254,920,000 shares $17.66 million +10.8%9.5%7.2 $3.59 2/15/20254,440,000 shares $16.38 million +2.5%8.6%6.1 $3.69 1/31/20254,330,000 shares $17.15 million -7.3%N/A5.2 $3.96 1/15/20254,670,000 shares $19.15 million +10.4%N/A5.4 $4.10 12/31/20244,230,000 shares $19.88 million -0.7%N/A4.8 $4.70 12/15/20244,260,000 shares $16.87 million -7.0%N/A4.1 $3.96 11/30/20244,580,000 shares $17.63 million -2.1%N/A2.7 $3.85 11/15/20244,680,000 shares $14.06 million -5.8%N/A2.8 $3.01 10/31/20244,970,000 shares $15.71 million -10.0%N/A3.1 $3.16 10/15/20245,520,000 shares $20.20 million -6.4%N/A3.3 $3.66 9/30/20245,900,000 shares $21.06 million -48.3%N/A3.5 $3.57 9/15/202411,400,000 shares $36.25 million +41.4%N/A6.8 $3.18 8/31/20248,060,000 shares $68.91 million -1.1%N/A8.7 $8.55 8/15/20248,150,000 shares $78.97 million +6.1%N/A9 $9.69 7/31/20247,680,000 shares $71.27 million +5.8%N/A8.8 $9.28 7/15/20247,260,000 shares $61.35 million +37.2%N/A9.3 $8.45 6/30/20245,290,000 shares $32.80 million +36.3%N/A7.2 $6.20 6/15/20243,880,000 shares $28.91 million +8.1%N/A6.8 $7.45 5/31/20243,590,000 shares $28.18 million +16.2%N/A6.7 $7.85 5/15/20243,090,000 shares $25.49 million +3.0%N/A5 $8.25 4/30/20243,000,000 shares $21.39 million +18.6%N/A5 $7.13 4/15/20242,530,000 shares $18.62 million +12.0%N/A4 $7.36 3/31/20242,260,000 shares $21.33 million -5.4%N/A3.4 $9.44 3/15/20242,390,000 shares $27.15 million -25.3%N/A3.4 $11.36 2/29/20243,200,000 shares $32.67 million -0.6%N/A4.5 $10.21 2/15/20243,220,000 shares $30.27 million -4.7%N/A5.1 $9.40 1/31/20243,380,000 shares $24.40 million -16.3%N/A5.5 $7.22 1/15/20244,040,000 shares $28.68 million +10.1%N/A6.7 $7.10 12/31/20233,670,000 shares $24.77 million +10.2%N/A6.5 $6.75 12/15/20233,330,000 shares $17.95 million -18.0%N/A6.2 $5.39 11/30/20234,060,000 shares $19.49 million +9.7%N/A7.8 $4.80 11/15/20233,700,000 shares $15.47 million -6.3%N/A6.1 $4.18 10/31/20233,950,000 shares $14.38 million +1.0%N/A2 $3.64 10/15/20233,910,000 shares $15.21 million -2.7%N/A1.9 $3.89 9/30/20234,020,000 shares $17.85 million +7.5%N/A2 $4.44 9/15/20233,740,000 shares $16.79 million +5.1%N/A1.8 $4.49 8/31/20233,560,000 shares $19.69 million +30.4%N/A1.7 $5.53 8/15/20232,730,000 shares $11.55 million -22.2%N/A1.3 $4.23 7/31/20233,510,000 shares $13.41 million +0.3%N/A5 $3.82 7/15/20233,500,000 shares $12.88 million -4.1%N/A4.6 $3.68 6/30/20233,650,000 shares $12.05 million -19.3%N/A4.6 $3.30 6/15/20234,520,000 shares $13.74 million +9.4%N/A5.3 $3.04 5/31/20234,130,000 shares $11.23 million +4.8%N/A4.1 $2.72 5/15/20233,940,000 shares $14.34 million -17.6%N/A3.2 $3.64 4/30/20234,780,000 shares $11.95 million -6.6%N/A3.9 $2.50 4/15/20235,120,000 shares $12.34 million +3.6%N/A4.2 $2.41 3/31/20234,940,000 shares $14.08 million +25.1%N/A3.8 $2.85 3/15/20233,950,000 shares $15.01 million -2.5%N/A3.1 $3.80 2/28/20234,050,000 shares $24.46 million +7.7%N/A3.8 $6.04 2/15/20233,760,000 shares $48.69 million +6.2%N/A3.8 $12.95 1/31/20233,540,000 shares $44.64 million +6.6%N/A4.6 $12.61 1/15/20233,320,000 shares $45.48 million -7.3%N/A4.6 $13.70 12/30/20223,580,000 shares $26.06 million +21.0%N/A5.7 $7.28 12/15/20222,960,000 shares $16.22 million -9.2%N/A6.1 $5.48 11/30/20223,260,000 shares $22.33 million -4.4%N/A8.5 $6.85 11/15/20223,410,000 shares $24.48 million -2.0%N/A8.9 $7.18 10/31/20223,480,000 shares $19.35 million +0.6%N/A8 $5.56 10/15/20223,460,000 shares $25.95 million -3.9%N/A7.5 $7.50 9/30/20223,600,000 shares $29.12 million -7.2%N/A8.4 $8.09 9/15/20223,880,000 shares $35.31 million +13.8%N/A8.4 $9.10 8/31/20223,410,000 shares $25.23 million +5.3%N/A5.3 $7.40 8/15/20223,240,000 shares $25.34 million -8.2%N/A4.6 $7.82 7/31/20223,530,000 shares $20.76 million -6.1%12.0%4.8 $5.88 7/15/20223,760,000 shares $20.27 million +1.4%12.8%5.1 $5.39 6/30/20223,710,000 shares $18.18 million +6.6%12.6%4.3 $4.90 6/15/20223,480,000 shares $15.35 million -7.0%11.8%3.9 $4.41 5/31/20223,740,000 shares $26.63 million +9.4%12.7%5 $7.12 5/15/20223,420,000 shares $28.32 million -21.7%11.6%4.7 $8.28 4/30/20224,370,000 shares $42.04 million +63.1%15.1%6.4 $9.62 4/15/20222,680,000 shares $35.48 million -0.4%9.3%4.4 $13.24 3/31/20222,690,000 shares $63.62 million -5.0%9.3%5.4 $23.65 3/15/20222,830,000 shares $44.52 million +12.8%9.8%6.6 $15.73 2/28/20222,510,000 shares $27.61 million -4.9%8.4%6 $11.00 2/15/20222,640,000 shares $29.81 million +25.7%8.8%6.5 $11.29 1/31/20222,100,000 shares $25.54 million +17.3%7.2%4.7 $12.16 1/15/20221,790,000 shares $24.92 million -2.7%N/A0 $13.92 12/31/20211,840,000 shares $32.55 million +8.2%6.1%4.1 $17.69 12/15/20211,700,000 shares $28.56 million -18.7%5.6%3.4 $16.80 11/30/20212,090,000 shares $30.31 million -31.0%6.9%3.9 $14.50 11/15/20213,030,000 shares $54.12 million +47.1%10.0%5.5 $17.86 10/29/20212,060,000 shares $45.61 million -0.5%6.9%0.6 $22.14 10/15/20212,070,000 shares $53.82 million +0.5%6.8%0.6 $26.00 9/30/20212,060,000 shares $58.11 million +21.2%6.7%0.6 $28.21 9/15/20211,700,000 shares $45.85 million +4.9%5.9%0.5 $26.97 8/31/20211,620,000 shares $48.11 million -35.5%6.2%0.5 $29.70 8/13/20212,510,000 shares $57.55 million +261.2%13.1%0.8 $22.93 7/30/2021695,000 shares $5.08 million -7.4%4.4%0.4 $7.31 7/15/2021750,400 shares $7.02 million -12.2%4.7%4.9 $9.36 6/30/2021855,000 shares $8.96 million +29.1%5.4%6 $10.48 6/15/2021662,500 shares $5.59 million -2.4%4.2%5.9 $8.44 5/28/2021678,600 shares $6.06 million -5.4%4.3%7.7 $8.93 5/14/2021717,100 shares $7.09 million -3.6%4.5%8 $9.89 4/30/2021743,500 shares $8.35 million -3.6%4.8%7.4 $11.23 4/15/2021771,100 shares $9.23 million +0.5%3.6%6.4 $11.97 3/31/2021767,600 shares $8.77 million +8.9%3.6%5.4 $11.43 3/15/2021705,000 shares $8.62 million +2.0%3.3%4.6 $12.22 2/26/2021691,000 shares $8.82 million -4.6%3.2%4.6 $12.77 2/12/2021724,100 shares $9.70 million +2.4%3.5%4.5 $13.40 1/29/2021707,500 shares $7.96 million -21.8%4.1%4.3 $11.25 1/15/2021904,800 shares $10.27 million -9.5%5.3%5.3 $11.35 12/31/20201,000,000 shares $12.69 million +13.2%6.8%6 $12.69 12/15/2020883,700 shares $11.80 million -5.1%6.0%4.7 $13.35 11/30/2020931,000 shares $10.74 million -9.6%6.3%4.6 $11.54 11/15/20201,030,000 shares $13.03 million -22.0%7.0%5.1 $12.65 10/30/20201,320,000 shares $13.11 million +9.1%9.7%5.5 $9.93 10/15/20201,210,000 shares $13.64 million +5.2%8.9%5 $11.27 9/30/20201,150,000 shares $9.12 million +34.6%8.5%5.4 $7.93 FULC Short Interest - Frequently Asked Questions What is Fulcrum Therapeutics' current short interest? Short interest is the volume of Fulcrum Therapeutics shares that have been sold short but have not yet been closed out or covered. As of August 31st, traders have sold 3,720,000 shares of FULC short. 7.39% of Fulcrum Therapeutics' shares are currently sold short. Learn More on Fulcrum Therapeutics' current short interest. What is a good short interest ratio for Fulcrum Therapeutics? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. FULC shares currently have a short interest ratio of 6.0. Learn More on Fulcrum Therapeutics's short interest ratio. Which institutional investors are shorting Fulcrum Therapeutics? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Fulcrum Therapeutics: Group One Trading LLC. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. What is a good short interest percentage for Fulcrum Therapeutics? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 7.39% of Fulcrum Therapeutics' floating shares are currently sold short. Is Fulcrum Therapeutics' short interest increasing or decreasing? Fulcrum Therapeutics saw a decline in short interest during the month of August. As of August 31st, there was short interest totaling 3,720,000 shares, a decline of 36.1% from the previous total of 5,820,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does Fulcrum Therapeutics' short interest compare to its competitors? 7.39% of Fulcrum Therapeutics' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Fulcrum Therapeutics: Vericel Corporation (11.50%), Avadel Pharmaceuticals PLC. (11.39%), Biohaven Ltd. (11.98%), Edgewise Therapeutics, Inc. (13.53%), Ardelyx, Inc. (9.35%), Schrodinger, Inc. (16.08%), Janux Therapeutics, Inc. (14.89%), Cogent Biosciences, Inc. (12.38%), Structure Therapeutics Inc. Sponsored ADR (12.28%), AbCellera Biologics Inc. (19.18%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: SPDR S&P 500 ETF Trust ($73.23 billion), Invesco QQQ ($29.52 billion), iShares Russell 2000 ETF ($20.82 billion), iShares 20+ Year Treasury Bond ETF ($10.76 billion), Palo Alto Networks, Inc. ($9.37 billion), Strategy Inc ($7.58 billion), Invesco S&P 500 Equal Weight ETF ($6.78 billion), SPDR S&P Biotech ETF ($6.72 billion), AppLovin Corporation ($6.37 billion), and iShares iBoxx $ Investment Grade Corporate Bond ETF ($6.29 billion). View all of the most shorted stocks. What does it mean to sell short Fulcrum Therapeutics stock? Short selling FULC is an investing strategy that aims to generate trading profit from Fulcrum Therapeutics as its price is falling. FULC shares are trading up $0.25 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Fulcrum Therapeutics? A short squeeze for Fulcrum Therapeutics occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of FULC, which in turn drives the price of the stock up even further. How often is Fulcrum Therapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including FULC, twice per month. The most recent reporting period available is August, 31 2025. More Short Interest Resources from MarketBeat Related Companies Vericel Short Interest Data Avadel Pharmaceuticals Short Interest Data Biohaven Short Interest Data Edgewise Therapeutics Short Interest Data Ardelyx Short Interest Data Schrodinger Short Interest Data Janux Therapeutics Short Interest Data Cogent Biosciences Short Interest Data Structure Therapeutics Short Interest Data AbCellera Biologics Short Interest Data Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:FULC) was last updated on 9/26/2025 by MarketBeat.com Staff From Our PartnersAnother gold high? Here’s the move Wall Street is missing …Gold has surged past $3,600 an ounce, up 45% in the last year, but Weiss Ratings analyst Sean Brodrick says th...Weiss Ratings | SponsoredNew Buy Alert: Should you put $1,000 into Oracle (ORCL) now?Barron's is calling this Oracle's "Nvidia Moment..." While the Wall Street Journal is simply calling Oracle...Chaikin Analytics | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | SponsoredWhy More Investors Are Using Family Trusts to Protect Their WealthFor many investors, a family trust can be an essential tool for protecting assets, avoiding probate, and ensur...SmartAsset | SponsoredStrange crypto pattern discovered by 40-person research teamSomething unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...Crypto Swap Profits | SponsoredIRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Fulcrum Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Fulcrum Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free FULC Stock Alerts